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Edited by Jesus AvilaAbstract Alzheimer’s disease is characterized by the deposition
of amyloid b-peptide (Ab) plaques in the brain. Full-length amy-
loid-b precursor protein (APP) is processed by a- and b-secreta-
ses to yield soluble APP derivatives and membrane-bound
C-terminal fragments, which are further processed by c-secre-
tase to a non-amyloidogenic 3 kDa product or to Ab fragments.
As diﬀerent Ab fragments contain diﬀerent parts of the APP
transmembrane helix, one may speculate that they are retained
more or less eﬃciently in the membrane. Here, we use the tran-
slocon-mediated insertion of diﬀerent APP-derived polypeptide
segments into the endoplasmic reticulum membrane to assess
the propensities for membrane retention of Ab fragments. Our
results show a strong correlation between the length of an Ab-de-
rived segment and its ability to integrate into the microsomal
membrane.
 2007 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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The aggregation of ﬁbrillar amyloid b-peptide (Ab) is
thought to be the primary neuropathological event in
Alzheimer’s disease (AD) [1]. Ab is a 4 kDa peptide, primarily
found as deposits (plaques) in the cerebral cortex and limbic
system of the Alzheimer brain [2]. Ab is an internal fragment
of the 110–120 kDa amyloid-b precursor protein (APP) [3].
Full-length APP is processed by at least three proteases (a-,
b- and c-secretase), Fig. 1. a-Secretase cleaves APP within
the Ab domain to generate a soluble N-terminal and a mem-
brane-bound C-terminal fragment (CTF) [4]. b-SecretaseAbbreviations: AD, Alzheimer’s disease; Ab, amyloid b-peptide; APP,
amyloid b-protein precursor; AICD, APP intracellular domain; CTF,
C-terminal fragment; TM, transmembrane; p3, 3 kDa product; ER,
endoplasmic reticulum; Lep, leader peptidase
*Corresponding author. Fax: +46 8 153679.
E-mail address: ingmarie@dbb.su.se (IngMarie Nilsson).
0014-5793/$32.00  2007 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2007.07.003produces carboxyl-terminal fragments of APP by cleaving in
its luminal domain [5]. Cleavage by a-secretase or b-secretase
within the luminal/extracellular domain results in the forma-
tion of the large soluble APP domains, called APPsa and
APPsb, respectively, and a membrane-attached carboxyl-ter-
minal fragment (aCTF or bCTF).
Finally, c-secretase cleaves bCTF in the middle of its trans-
membrane domain, leading to the release of Ab, Fig. 1. Iden-
tiﬁcation of multiple cleavage sites within the APP molecule
has suggested that APP can also be cleaved by other proteases,
namely e- and f-secretases, that also generate an intracellular
CTF domain (AICD) and longer Ab fragments [6–8].
As diﬀerent Ab and CTF variants contain diﬀerent portions
of the APP transmembrane segment, one may suspect that
they are released from the endoplasmic reticulum (ER) mem-
brane to diﬀerent degrees. Presumably, the formation of toxic
aggregates will only take place after release of Ab from the
membrane, and ineﬃciently released fragments may hence be
less toxic. In this study, we have measured the ability of diﬀer-
ent Ab and CTF segments to insert into the membrane of
microsomal vesicles derived from dog pancreas, using a system
that allows precise measurement of the eﬃciency of membrane
insertion of hydrophobic segments engineered into a model
protein [9]. We ﬁnd that association with the membrane is crit-
ically dependent on the length and the hydrophobicity of APP
segment.2. Material and methods
2.1. Enzymes and chemicals
All enzymes, plasmid pGEM1, DTT, and the TnT coupled tran-
scription/translation system were from Promega (Madison, WI).
[35S]-Met and deoxyribonucleotides were from GE-Healthcare (Upp-
sala, Sweden). Oligonucleotides were from Cybergene (Stockholm,
Sweden).2.2. Plasmid construction
Site-speciﬁc mutagenesis was performed using the QuikChange
Site-Directed Mutagenesis kit from Stratagene (La Jolla, USA). All
mutants were conﬁrmed by sequencing of plasmid DNA at BM labbet
AB (Furulund, Sweden). All cloning steps were done according to
standard procedures using restriction enzymes from Promega (Madi-
son, USA).blished by Elsevier B.V. All rights reserved.
Fig. 1. A schematic diagram of APP. The amyloid b peptide (Ab)
region contains part of the transmembrane domain (black box) and
part of the extracellular domain of APP (green box). Cleavage by b-
secretase generates the N terminus, and intramembranous cleavage by
c-secretase gives rise to the C terminus of Ab. Cleavage by a-secretase
precludes Ab formation. Eleven mis-sense mutations in the transmem-
brane region of APP are shown, together with the suggested cleavage
sites for e- and n-secretases. Red letters indicate mutations tested here.
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H-segment-containing Lep constructs carrying acceptor sites for N-
linked glycosylation in positions 96–98 (Asn-Ser-Thr; G1) and 258–260
(Asn-Ala-Thr; G2) [9] were expressed from the pGEM1 plasmid.
Oligonucleotides encoding the diﬀerent H-segment APP fragments
(Ab peptides and CTF fragments) were introduced as previously de-
scribed [9]. To mimic the natural Ab peptide, tandem translation stop
codons (TAG TAA) were introduced at the end of the APP fragment,
together with an extra acceptor site N-terminal of the natural APP TM
segment at positions 27–29 (Asn-Lys-Thr) in the Ab peptide using
mutagenesis. To examine known human mutations in the APP domain
and to insert proline residues in the AbTM segment, the desired amino
acid was altered by site-speciﬁc mutagenesis. All APP inserts were con-
ﬁrmed by sequencing of plasmid DNA.
2.4. Expression in vitro
Constructs in pGEM1 were transcribed and translated in the TnT
Quick systems from Promega. One microgram of DNA template,
1 ll [35S]-Met (5 mCi) and 2 equiv. of dog pancreas rough microsomes
[10] were added at the start of the reaction, and samples were incu-
bated for 90 min at 30 C. Translation products were analyzed by
SDS–PAGE and gels were visualized in a Fuji FLA-3000 phosphoim-
ager and analyzed using the Image Reader 8.1j software.
The degree of membrane release of each APP fragment was quanti-
ﬁed from SDS–PAGE gels (Fig. 3) by calculating the quotient between
the intensity of the doubly glycosylated band divided by the summed
intensities of the singly glycosylated and doubly glycosylated bands.
On average, glycosylation levels vary by no more than ±2% between
repeat experiments and all data points are mean values from at least
two independent experiments.3. Results
3.1. Model protein and membrane insertion assay
To estimate the degree of membrane retention of diﬀerent
Ab fragments, we used a previously developed experimental
system for measuring the eﬃciency of translocon-mediated
insertion into the ER membrane of hydrophobic segments in
membrane proteins [9]. Although the translocon is a compli-
cated molecular machine [11,12], the available data suggest
that translocon-mediated membrane insertion of hydrophobic
segments is driven by peptide–lipid interactions [9,13–15].
Therefore, Ab fragments should behave similarly in the mem-
brane-insertion assay as they do after presenilin processing.
As in our earlier studies of protein insertion into the ER
membrane, we used the well-characterized Escherichia coli in-
ner membrane protein leader peptidase (Lep) as a model pro-
tein [9,16] to study the translocon-mediated membraneinsertion of diﬀerent APP-derived polypeptide segments. Lep
consists of two transmembrane segments (H1, H2) connected
by a short cytoplasmic loop (P1) and a large C-terminal peri-
plasmic domain (P2). When expressed in vitro in the presence
of dog pancreas rough microsomes, Lep adopts the same
topology as in E. coli, with both the N terminus and the C-ter-
minal P2 domain located in the lumen of the microsome [17].
The microsomes used in the assay are prepared from pancreas
and not brain but, since the Sec61 translocon is the same in
both tissues, the source of the preparation should not matter
to the results.
We have constructed an engineered version of Lep [9] that
allows quantitative measurements of the eﬃciency of mem-
brane insertion of short polypeptide segments such as the Ab
fragments, Fig. 2A. Brieﬂy, polypeptide segments correspond-
ing to diﬀerent Ab segments are engineered into the P2 do-
main, 150 residues downstream of the H2 transmembrane
segment. In addition, two Asn-X-Thr acceptor sites for N-
linked glycosylation are present in the P2 domain: one (G1) be-
tween the H2 segment and the Ab segment, and the other (G2)
just downstream of the Ab segment. After in vitro translation
in the presence of microsomes, the degree of insertion into the
membrane of a given Ab segment can be quantiﬁed by com-
paring the fractions of singly glycosylated (i.e., membrane-
integrated) and doubly glycosylated (i.e., released) molecules.
We have also used a diﬀerent version of Lep in which the Ab
segment is present at the very C terminus of the molecule and
where the G2 glycosylation site is placed immediately up-
stream of the Ab segment. With this construct we can measure
the membrane integration eﬃciency of Ab segment with a free
C terminus, more closely mimicking the situation after cleav-
age of the APP transmembrane segment by presenilin.3.2. Membrane insertion of Ab segments
To examine the membrane integration of diﬀerent Ab and
C-terminal APP segments, we ﬁrst introduced the chosen seg-
ments into the P2 domain of full-length Lep and measured the
insertion into the ER membrane of Ab 40, 42, 43, 45, 46, 48,
49 and the C-terminal segments C50, C57, C59 [6,18–21], Table
SI. As expected, the natural APP transmembrane segment (Ab
TM from Gly700 to Leu723) is eﬃciently retained into the
membrane (96–97% singly glycosylatedmolecules, bothwithout
and with additional ﬂanking residues from APP), Fig. 2B. The
shorter Ab 40–43 segments, in contrast, are not retained in the
ER membrane. Ab 45 is released to about 34%, while little or
no release is seen for Ab 46–49, Figs. 2C and 4A.
The corresponding C-terminal segments show a similar
behavior, with shorter segments being less eﬃciently inte-
grated. The CTF 50 segment is eﬃciently released from the
ER membrane (88% doubly glycosylated molecules) while
CTF 57 is released to 60% and CTF 59 hardly at all, Fig. 4A.3.3. Membrane insertion of Ab(stop) segments
In the above constructs, the Ab segments are embedded
within the larger full-length model protein. To more closely
mimic the context of the hydrophobic segment in the natural
Ab peptides which, after cleavage by c-, f- or e-secretase, is lo-
cated at the very C-terminus of the peptide, we added stop co-
dons after the Ab segments and measured the eﬃciency of
integration of these truncated constructs into the microsomal
membrane. To this end, we introduced a new glycosylation
Fig. 2. Translocon-mediated membrane insertion of diﬀerent Ab and CTF constructs. (A) The leader peptidase model protein. Wild-type leader
peptidase (Lep) has two transmembrane helices (H1, H2) and a large lumenal domain (P2). It inserts into rough microsomes in an Nlum–Clum
orientation. In the constructs reported here, Ab 40–49 and CTF C50–59 segments (see Table S1) were inserted into the P2 domain in the position
indicated (H, gray rectangle), and Asn-X-Thr glycosylation acceptor sites (G1, G2) were introduced on both sides of the Ab and CTF segments.
Constructs in which the Ab or CTF segment is integrated into the endoplasmic reticulum (ER) membrane become glycosylated only on the G1 site
(left), whereas those in which the segment is translocated across the ER membrane become glycosylated on both the G1 and G2 sites (right). (B) In
vitro translation in the presence of dog pancreas rough microsomes (RMs) of constructs containing the Ab transmembrane segment with (lane TMF)
and without (lane TM) additional ﬂanking residues from APP (see Table S1). (C) In vitro translation in the presence of dog pancreas rough
microsomes of constructs containing the indicated Ab segments. Unglycosylated, singly glycosylated, and doubly glycosylated forms of the protein
are indicated by one open circle, one ﬁlled circle and two ﬁlled circles, respectively. The percentage of molecules not retained in the membrane is given
below the lanes (average and standard deviation of at least three independent experiments).
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to the natural APP TM segment, Fig. 3A and Table SI. As an
Asn-X-Thr glycosylation acceptor site must be located at least
14–15 residues from the membrane for eﬃcient glycosylation
[17], the G2 0 site will only be glycosylated if the Ab segment
is released from the membrane, whereas the G1 site will be gly-
cosylated regardless of whether the segment is released or not.
For the truncated Ab constructs, 60% release was seen for
the Ab 46* construct (Figs. 3B and 4A), demonstrating that
the C-terminal Ab(stop) segments are slightly less eﬃciently
integrated into the membrane than when they are embedded
within the Lep P2 domain.A number of known mutations associated with AD are lo-
cated in the Ab hydrophobic domain [22–25], Fig. 1. We se-
lected four in which a hydrophobic residue is replaced by a
more polar residue or vice versa for analysis: Thr714Ile,
Ile716Thr, Val717Gly, and Leu723Pro (Fig. 1, indicated in
red). The degree of membrane integration was measured for
the ﬁrst three in diﬀerent Ab(stop) constructs (Table S1); in
no case did the mutation change the fraction of integrated mol-
ecules, Table S2. The toxicity of these mutant Ab peptides
therefore seems not to be associated with their degree of mem-
brane retention but rather must reﬂect their aggregation pro-
pensity per se. The Leu723Pro mutation was tested in the
Fig. 3. Insertion of truncated Ab(stop) constructs into microsomal
membranes. (A) The truncated Lep construct used. In addition to the
G1 glycosylation site, a second Asn-X-Thr site (G2 0) has been
introduced just upstream of the Ab(stop) segment (see Table S1).
Constructs in which the Ab(stop) segment is released from the
membrane become glycosylated on both the G1 and G2 0 sites (right),
whereas constructs in which the Ab(stop) segment is retained in the
membrane are glycosylated only on the G1 site (left; see text). (B) In
vitro translation in the presence of dog pancreas rough microsomes of
constructs containing two diﬀerent Ab (stop) segments. Unglycosy-
lated, singly glycosylated and doubly glycosylated forms of the protein
are indicated by one open circle, one ﬁlled circle and two ﬁlled circles,
respectively. The percentage of molecules not retained in the mem-
brane is given below the lanes (average and standard deviation of at
least three independent experiments).
Fig. 4. (A) Insertion of Ab segments (gray dashed line, ﬁlled triangle),
Ab(stop) segments (black line, ﬁlled circles) and CTF segments (gray
dashed line, ﬁlled squares) into the microsomal membrane. The
percentage of molecules not integrated into the membrane (average
and standard deviation of at least three independent experiments) is
shown as a function of segment length. (B) Membrane integration of
Ab(stop) segments containing a proline residue in position 37 or 43.
The percentage of molecules not retained in the membrane (average
and standard deviation of at least two independent experiments) is
shown.
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integrated CTF decreased from 37% to 5%, Table S2.
As our previous studies on membrane integration of trans-
membrane segments have suggested that eﬃcient integration
depends on the formation of an a-helical structure [9], we also
made a set of constructs where a helix-breaking proline residue
was inserted in the Ab(stop) segments. We measured the mem-
brane insertion of three Ab(stop) constructs (Ab 46*, 48* and
51
*
) with a proline residue either at position 37 or 43, Table
SI. A signiﬁcant decrease in insertion eﬃciency was seen for
all constructs (Fig. 4B), suggesting that the membrane-inte-
grated forms of Ab must adopt a helical conformation.Fig. 5. Model for Ab-fragment release from the membrane. Mature
APP is cleaved by b-secretase, releasing a soluble N-terminal fragment
(APPsb). The C-terminal fragment (CTF) is produced by e-secretase
cleavage together with Ab 48–49 membrane-bound fragments. Longer
Ab fragments are further processed by f/c-secretases, leaving Ab 46
partly in the membrane while shorter, less hydrophobic fragments (Ab
40–45) are released into the lumen of the ER.4. Discussion
How eﬃciently are diﬀerent Ab peptides released from the
membrane upon cleavage by c-, f- or e-secretase? To address
this question, we have carried out a detailed study of the tran-
slocon-mediated insertion of diﬀerent APP segments into
microsomal membranes. Two diﬀerent series of Ab segments
– one truncated at the C-terminus and one with a long C-ter-
minal tail – yield similar results: shorter Ab segments (Ab 40–
45) are not integrated into the membrane, while longer ones(Ab 46–49) are eﬃciently retained in the membrane, Fig. 5.
Membrane integration of the diﬀerent CTFs shows a similar
dependency on the length of the remaining part of the APP
transmembrane segment.
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the literature: either c-, f- and e-cleavage are correlated with
each other [6,19], or the c- and e-cleavage are independent pro-
cesses [8,22]. Ihara and coworkers identiﬁed only two species
of AICDs (C50 and C51), despite detection of various Ab spe-
cies (Ab 40, 42, 43, 45, 46, 48, and 49) [18,19,21]. They, there-
fore, proposed a model in which longer Abs are processed
stepwise at every third residue by c-secretase. In the context
of this model, we would suggest that the stepwise processing
occurs only for those Ab species that are hydrophobic enough
to be retained in the membrane. The intermediate products Ab
48/49 would be generated by e-secretase cleavage, the Ab 48
and Ab 49 products would be further processed by f- and c-
secretase to generate Ab 45/46, and ﬁnally be released only
when further cleaved to yield Ab 40/42 [6].
Three known human mutations, Thr714Ile, Ile716Thr, and
Val717Gly, which are close to the c-secretase site and therefore
suggested to change the pattern of APP processing, had no ef-
fect on the eﬃciency of Ab segment insertion. The Leu723Pro
mutation did, however, decrease the insertion of the CTF seg-
ment C57 into the membrane. Results for Ab(stop) segments
containing proline residues further suggest that the formation
of an a-helical structure in the membrane-embedded part of
Ab is critical for eﬃcient retention in the membrane.
In conclusion, we have demonstrated that diﬀerent Ab seg-
ments are integrated into the ER membrane to diﬀerent de-
grees, depending on their overall length, hydrophobicity and
helix potential. We speculate that this might also aﬀect their
access to the secretases in the ER membrane and their ability
to partake in the formation of toxic aggregates.
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